Cambridge Cognition positioned to grow revenues and move into profitability

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, is pleased to announce the formation of a Scientific Advisory Board. This expert board will provide scientific guidance and valuable market insights, primarily focusing

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced a new strategic partnership with ActiGraph, a leading provider of wearable technologies for clinical trials. The partnership will deliver a

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced the appointment of Stuart Gall and Philip Rodgers as independent non-executive Directors of the Company, both with effect from 1

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced that on 15 December 2023, the Company granted options over a total of 1,012,465 ordinary shares of 1 pence each

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced that the Board has approved the appointment of Crowe UK LLP as the Group’s new external auditor following a competitive

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced the launch today of AQUA, the Company’s automated quality assurance solution for central nervous system clinical trials that is powered

Cambridge Cognition (LON:COG), which develops and markets digital solutions to assess brain health, has announced that it has secured a significant contract for a sizeable later stage clinical trial, following a competitive tender. The contract combines the

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced that the Company has obtained a £3.0 million loan from Claret European Specialty Lending Company III, S.à r.l.  Claret specialises in

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, stated that it will announce its unaudited interim results for the six months ended 30 June 2023 on Tuesday 26 September 2023.

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced it has won a £2 million contract for a pivotal cancer therapy trial. The Company will provide its proprietary

Cambridge Cognition (LON:COG), which develops and markets digital solutions to assess brain health, has announced that the explanatory note to Resolution 7 in the Notice of the Annual General Meeting (“AGM”) to be held on 28 June 2023

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has confirmed that the Annual Report and Accounts for the year ended 31 December 2022 and the Notice of the Annual General

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced that it will be hosting a Capital Markets Day on 14 June 2023 at 14:00 in the Great Room

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced its preliminary audited results for the year ended 31 December 2022. 2022 performance Cambridge Cognition had a transformative year

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, will be announcing the Company’s preliminary financial results for the year ended 31 December 2022 on Wednesday 3 May 2023 and